about
Pulmonary arterial hypertension in adults: novel drugs and catheter ablation techniques show promise? Systematic review on pharmacotherapy and interventional strategies.Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.Comorbidities frequency in Takotsubo syndrome: an international collaborative systematic review including 1109 patients.Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.Long-term outcome of nonobstructive versus obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis.New oral anticoagulants and dual antiplatelet therapy: Focus on apixaban.The challenge of performing effective medical research in the era of healthcare data protection.Transparency in medical research: Time for a paradigm shift.The elusive link between sex hormone levels and Takotsubo syndrome.Takotsubo is not a cardiomyopathy.Diastolic function in Takotsubo: Looking for a new piece of a complex puzzle.A novel ultrafast-low-dose computed tomography protocol allows concomitant coronary artery evaluation and lung cancer screening.Sex-related differences in cardiomyopathiesThe replyTakotsubo: One, no one and one hundred thousand diseasesNet clinical benefit of patent foramen ovale closure in patients with cryptogenic stroke: Meta-analysis and meta-regression of randomized trialsUsefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin TreatmentMeta-Regression to Identify Patients Deriving the Greatest Benefit from Dual Antiplatelet Therapy after Stroke or Transient Ischemic Attack Without Thrombolytic or Thrombectomy TreatmentThe replyThe ReplyLong-term outcome of patients with ST-segment elevation myocardial infarction treated with low-dose intracoronary thrombolysis during primary percutaneous coronary intervention: the 5-year results of the DISSOLUTION Trial
P50
Q33810499-D96A3A47-3C2D-46D9-B2F1-9B0FAF18CEDFQ38281539-BF73476C-31E9-43D7-9696-A5F2DDBE7665Q38347183-AC30DA66-92D0-4518-9B0E-D54439414D18Q38592653-D01A7109-4745-4BAD-9A0D-00B6702162C0Q38659796-D8419BCD-905F-4F28-8362-9AAC2DB4D326Q38977093-FEB5E2AA-4355-4C10-8150-9F5FE5E9A86BQ45794456-1A00E5A0-B72E-4B03-B8E9-D4DE75E93A9FQ48042729-058E7CD9-90BF-405B-AA51-EE8C111EF0E2Q49709177-A9178AFC-2037-4448-963C-B27AB6215E52Q49838772-E3A820B9-3201-42E2-949E-ACE4FD59346DQ52549172-9CF33967-23E7-4F85-8C30-42D29589D188Q55021534-8538AA5E-8D73-48A9-9DC8-DB9C361C08E9Q58592286-66295DF0-8070-47EF-8DE0-3FBEBD8E2093Q86998812-78282CE1-01D9-440A-B228-0118E1D9CD6DQ88363891-CCEC18F8-69F4-4FDE-80BE-D5AF6193DBFDQ89055547-0E11F570-BCEA-4B42-96FD-1F97DD5091F9Q93014020-C44C52AA-E1D1-456B-8334-D239B9550369Q93084558-21A03C37-A237-4921-9BFF-1E60A1B28F8AQ95414694-54FD4BBA-E7CC-435B-BA13-B79465DFA3D3Q95461839-0613C267-13CC-4C43-9D28-A171B3D03E44Q96023701-EA8962D0-B2A9-43B5-B595-1CBED4D116A3
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Francesco Pelliccia
@ast
Francesco Pelliccia
@en
Francesco Pelliccia
@es
Francesco Pelliccia
@nl
type
label
Francesco Pelliccia
@ast
Francesco Pelliccia
@en
Francesco Pelliccia
@es
Francesco Pelliccia
@nl
prefLabel
Francesco Pelliccia
@ast
Francesco Pelliccia
@en
Francesco Pelliccia
@es
Francesco Pelliccia
@nl
P106
P21
P31
P496
0000-0003-1260-1308